Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes-Reference-Cited by-同舟云学术

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes

Published:2019-08-29 Issue:3 Volume:188 Page:394-403
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Abeykoon Jithma P.¹^ORCID,Zanwar Saurabh¹^ORCID,Ansell Stephen M.¹,Gertz Morie A.¹,Kumar Shaji¹^ORCID,Manske Michelle¹,Novak Anne J.¹,King Rebecca²,Greipp Patricia³,Go Ronald¹,Inwards David¹,Muchtar Eli¹^ORCID,Habermann Thomas¹,Witzig Thomas E.¹,Thompson Carrie A.¹,Dingli David¹,Lacy Martha Q.¹,Leung Nelson¹,Dispenzieri Angela¹,Gonsalves Wilson¹^ORCID,Warsame Rahma¹,Kyle Robert A.¹,Rajkumar Vincent¹,Parikh Sameer A.¹^ORCID,Kapoor Prashant¹

Affiliation:

1. Division of Hematology, Department of Internal Medicine Mayo Clinic Rochester MN USA

2. Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

3. Division of Laboratory Genetics Mayo Clinic Rochester MN USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16168

Reference29 articles.

1. New developments in the management of Waldenström macroglobulinemia